Table 1.
Patient characteristics
| Factor | Overall n/N (%) | MGUS | AMM | P value |
|---|---|---|---|---|
| Age ≥65 y | 143/331 (43%) | 63/152 (41%) | 80/179 (45%) | .553 |
| Female | 153/331 (46%) | 77/152 (51%) | 76/179 (42%) | .136 |
| SWOG performance status 0 | 228/327 (70%) | 101/151 (67%) | 127/176 (72%) | .301 |
| Hemoglobin <12 g/dL | 84/331 (25%) | 32/152 (21%) | 52/179 (29%) | .096 |
| Platelets <240 × 103/μL* | 206/331 (62%) | 88/152 (58%) | 118/179 (66%) | .133 |
| Albumin <4 g/dL* | 154/329 (47%) | 64/151 (42%) | 90/178 (51%) | .139 |
| Serum B2M >3 mg/L* | 86/322 (27%) | 31/147 (21%) | 55/175 (31%) | .037 |
| Serum B2M >5.5 mg/L | 17/322 (5%) | 8/147 (5%) | 9/175 (5%) | 1.000† |
| Bone marrow PCs ≥10% | 176/330 (53%) | 0/152 (0%) | 176/178 (99%) | <.001 |
| Bone marrow PCs ≥20%* | 84/330 (25%) | 0/152 (0%) | 84/178 (47%) | <.001 |
| Bone marrow PCs ≥60% | 2/330 (1%) | 0/152 (0%) | 2/178 (1%) | .502† |
| Serum M-protein ≥3 g/dL* | 34/330 (10%) | 0/152 (0%) | 34/178 (19%) | <.001 |
| Urine M-protein >0 | 48/227 (21%) | 21/110 (19%) | 27/117 (23%) | .462 |
| IgA isotype M-protein | 45/313 (14%) | 14/138 (10%) | 31/175 (18%) | .058 |
| IgG isotype M-protein | 264/313 (84%) | 121/138 (88%) | 143/175 (82%) | .149 |
| Light chain only | 4/313 (1%) | 3/138 (2%) | 1/175 (1%) | .324† |
| Uninvolved immunoglobulins low‡ | 212/309 (69%) | 66/135 (49%) | 146/174 (84%) | <.001 |
| κ light chain clonal isotype | 190/303 (63%) | 86/137 (63%) | 104/166 (63%) | .982 |
| Invovlved/uninvolved SFLC ratio >10* | 79/228 (35%) | 13/87 (15%) | 66/141 (47%) | <.001 |
| Involved SFLC >25 mg/dL | 42/228 (18%) | 10/87 (11%) | 32/141 (23%) | .034 |
| Abnormal metaphase cytogenetics | 24/250 (10%) | 5/95 (5%) | 19/155 (12%) | .068 |
| CD4 <920/μL | 121/178 (68%) | 42/66 (64%) | 79/112 (71%) | .341 |
| GEP 70-gene risk >−0.26* | 37/126 (29%) | 6/39 (15%) | 31/87 (36%) | .021 |
| GEP poly-PC >11.60* | 62/126 (49%) | 32/39 (82%) | 30/87 (34%) | <.001 |
| GEP PI >−2.73* | 50/126 (40%) | 10/39 (26%) | 40/87 (46%) | .031 |
| GEP CD-1 subgroup | 6/126 (5%) | 3/39 (8%) | 3/87 (3%) | .373† |
| GEP CD-2 subgroup | 28/126 (22%) | 14/39 (36%) | 14/87 (16%) | .013 |
| GEP HY subgroup | 31/126 (25%) | 4/39 (10%) | 27/87 (31%) | .012 |
| GEP LB subgroup | 28/126 (22%) | 10/39 (26%) | 18/87 (21%) | .537 |
| GEP MF subgroup | 17/126 (13%) | 6/39 (15%) | 11/87 (13%) | .677 |
| GEP MS subgroup | 11/126 (9%) | 1/39 (3%) | 10/87 (11%) | .170† |
| GEP PR subgroup | 5/126 (4%) | 1/39 (3%) | 4/87 (5%) | 1.000† |
| MRI focal lesions ≥1 | 25/156 (16%) | 7/64 (11%) | 18/92 (20%) | .148 |
| MRI focal lesions >1 | 9/156 (6%) | 3/64 (5%) | 6/92 (7%) | .738† |
CD-2, cyclin D-2; HY, hyperdiploid; LB, low bone; n, number with factor; N, number with valid data for factor; PI, proliferation index; poly-PC, polyclonal PCs.
*
Optimal cut-points when applicable are based on approximate running log-rank test statistic.
†
P values computed using Fisher's exact test.
‡
Uninvolved immunoglobulins low: <600 mg/dL if IgG, <50 mg/dL if IgM, <100 mg/dL if IgA.